BioHarvest Sciences (NASDAQ:BHST) Now Covered by Craig Hallum

Craig Hallum assumed coverage on shares of BioHarvest Sciences (NASDAQ:BHST) in a research report released on Monday morning, MarketBeat.com reports. The brokerage issued a buy rating and a $15.00 target price on the stock.

Separately, HC Wainwright reiterated a “buy” rating and set a $14.00 target price on shares of BioHarvest Sciences in a research report on Tuesday, April 8th.

BioHarvest Sciences Price Performance

Shares of NASDAQ:BHST opened at $6.39 on Monday. The company has a market capitalization of $104.96 million, a PE ratio of -5.12 and a beta of 0.80. The stock has a fifty day simple moving average of $5.93. BioHarvest Sciences has a 1 year low of $6.39 and a 1 year high of $7.38.

BioHarvest Sciences (NASDAQ:BHST) last issued its quarterly earnings results on Monday, March 31st. The company reported ($0.17) EPS for the quarter, missing the consensus estimate of ($0.12) by ($0.05). The business had revenue of $7.17 million during the quarter, compared to the consensus estimate of $7.24 million. On average, equities analysts anticipate that BioHarvest Sciences will post -0.8 earnings per share for the current year.

Institutional Trading of BioHarvest Sciences

An institutional investor recently raised its position in BioHarvest Sciences stock. Magnus Financial Group LLC grew its position in BioHarvest Sciences Inc. (NASDAQ:BHST) by 105.0% in the 1st quarter, according to its most recent filing with the Securities & Exchange Commission. The firm owned 71,733 shares of the company’s stock after buying an additional 36,733 shares during the period. Magnus Financial Group LLC owned approximately 0.44% of BioHarvest Sciences worth $444,000 at the end of the most recent quarter.

About BioHarvest Sciences

BioHarvest Sciences Inc is a biotech firm. It focused on leveraging its botanical synthesis technology to develop science-based and clinically proven therapeutic solutions, within business verticals nutraceutical health and wellness products such as dietary supplements and development of plant cell-based Active Pharmaceutical Ingredients which focus on specific medical indications.